ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck
From BioSpace · · 27 min
This plays from the publisher's own server. We do not host a copy.
Description
At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago this past weekend, packed plenary sessions from Revolution Medicines (https://www.biospace.com/drug-development/asco-revolution-poised-to-capture-ras-space-as-pancreatic-cancer-dataset-derisks-approval) and Summit Therapeutics’ Chinese partner Akeso stole the show (https://www.biospace.com/drug-development/asco-akesos-vegf-pd-1-boosts-lung-cancer-survival-relieving-pressure-on-us-partner-summit). For RevMed, analysts anticipate a potential approval in pancreatic cancer as early as this year, while Summit still has a tough road ahead showing that the survival benefit seen in Akeso’s clinical trial in China will hold up in a global population (https://www.biospace.com/drug-development/asco-summit-reached-with-china-lung-data-but-new-climb-begins-to-prove-global-benefit).
Immuneering (https://www.biospace.com/drug-development/asco-biopharma-has-pancreatic-cancer-surrounded-as-immuneerings-drug-adds-9-quality-months), BMS/BioNTech (https://www.biospace.com/drug-development/asco-a-battle-of-bispecifics-eli-lillys-big-win-and-more), Merck (https://www.biospace.com/drug-development/asco-merck-overshadowed-by-upstart-biotechs-but-trop2-plans-begin-to-pay-off), Pfizer (https://www.biospace.com/drug-development/asco-pfizer-scores-in-lung-colorectal-and-prostate-cancer-but-key-readouts-still-to-come) and many more also scored oncology wins at the annual meeting, as did Moderna, with “encouraging” 5-year survival (https://www.biospace.com/drug-development/asco-modernas-mrna-based-melanoma-vaccine-shows-encouraging-5-year-survival) for its mRNA-based personalized melanoma vaccine.
Outside of ASCO, the past week saw Pfizer strike an unusual pact (https://www.biospace.com/business/pfizer-bets-up-to-10-5b-in-12-candidate-cancer-collab-with-chinas-innovent) with China’s Innovent Biologics as it seeks to bolster its oncology pipeline (https://www.biospace.com/drug-development/asco-pfizer-scores-in-lung-colorectal-and-prostate-cancer-but-key-readouts-still-to-come). Reminiscent of another recent deal from BMS and Hengrui Pharma, it could signal a more collaborative approach (https://www.biospace.com/deals/big-pharma-makes-creative-effort-to-fold-chinese-assets-into-pipelines) to working with Chinese companies. We’ll also cover the latest deals from Eli Lilly, which continues to rack up partners with its GLP-1 windfall.
Finally, learn about how BrainStorm is planning another FDA bid for its experimental ALS therapy NurOwn (https://www.biospace.com/drug-development/brainstorm-levels-up-bringing-on-former-fda-leader-peter-pitts-for-new-als-bid) with former regulator Peter Pitts now on the board, and check out a preview (https://www.biospace.com/drug-development/obesity-davids-and-goliaths-face-off-at-ada-2026) of the 2026 American Diabetes Association, or ADA, which kicks off this weekend in New Orleans.